Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$56.38

-3.89 (-6.45%)

07:25
11/15/18
11/15
07:25
11/15/18
07:25

Blueprint Medicines to hold a conference call

Management presents updated results from the NAVIGATOR Trial of Avapritinib in advanced BIST presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting on a conference call to be held on November 15 at 7:30 am. Webcast Link

  • 15

    Nov

BPMC Blueprint Medicines
$56.38

-3.89 (-6.45%)

09/24/18
LEER
09/24/18
INITIATION
Target $105
LEER
Outperform
Blueprint Medicines initiated with an Outperform at Leerink
Leerink analyst Andrew Berens started Blueprint Medicines with an Outperform rating and $105 price target.
09/26/18
PIPR
09/26/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo RET inhibitor still looks superior to Blueprint's, says Piper Jaffray
Loxo Oncology (LOXO) provided an update of the Phase I/II Libretto study of LOXO-292, the company's RET inhibitor and the vast majority of the current valuation, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. While the overall response rate dropped slightly from 77% to 68% in more patients, it still appears superior to Blueprint Medicines' (BPMC) competing BLU-667, which has thus far demonstrated a 47% response rate in a similar patient population, the analyst contends. Van Buren adds that he's unconcerned by the two new grade three adverse events reported. He believes there "may very well" be upside to his current $1.5B peak sales estimate by the mid-2020s. The analyst reiterates an Overweight rating on Loxo Oncology with a $200 price target.
09/26/18
STFL
09/26/18
NO CHANGE
Target $217
STFL
Buy
Loxo data not 'transformational,' but keeps inspiring confidence, says Stifel
Stifel analyst Stephen Willey said the incremental follow-up data from Loxo Oncology's (LOXO) LIBRETTO-001 trial isn't "transformational," but it does confirm his confidence in the establishment of a high competitive hurdle for LOXO-292, which he sees being a "best-in-class" and first-to-market asset in a $1B+ market. He remains confident LOXO-292 is the superior asset, but acknowledges the anticipation of Blueprint Medicines' (BPMC) updated BLU-667 data at some point in late-FY18 to early-FY19 could serve as a bit of headwind on Loxo shares nearer to that data release. Willey keeps a Buy rating and $217 price target on Loxo shares.
10/07/18
PIPR
10/07/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo Oncology's 292 remains on top after RET data updates, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $200 price target for Loxo Oncology (LOXO) after the company provided an update of the thyroid patients in the Phase I/II study of LOXO-292. The analyst highlights that in the largest patient population the response rate increased from 45% to 59% with three additional patients responding between 9 and 12 months. Blueprint Medicines' (BPMC) competing BLU-667 reported a 49% ORR in a similar patient population and recall that adverse events of hypertension are still a concern, he notes. Van Buren believes that the 667's safety profile could continue to look worse as it continues to administer the drug to patients at higher doses and that treatment discontinuations could increase. Overall, the analyst believes Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety and could easily become a $1B+ drug.

TODAY'S FREE FLY STORIES

PLWTY

Panalpina

$0.00

(0.00%)

08:44
01/21/19
01/21
08:44
01/21/19
08:44
Downgrade
Panalpina rating change  »

Panalpina downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFGSY

Eiffage

$0.00

(0.00%)

08:41
01/21/19
01/21
08:41
01/21/19
08:41
Upgrade
Eiffage rating change  »

Eiffage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVFCF

Television Francaise 1

$0.00

(0.00%)

08:40
01/21/19
01/21
08:40
01/21/19
08:40
Downgrade
Television Francaise 1 rating change  »

Television Francaise 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVDY

Atresmedia

$0.00

(0.00%)

08:37
01/21/19
01/21
08:37
01/21/19
08:37
Upgrade
Atresmedia rating change  »

Atresmedia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDPAY

Tod's

$0.00

(0.00%)

08:36
01/21/19
01/21
08:36
01/21/19
08:36
Downgrade
Tod's rating change  »

Tod's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFRGY

Salvatore Ferragamo

$0.00

(0.00%)

08:35
01/21/19
01/21
08:35
01/21/19
08:35
Downgrade
Salvatore Ferragamo rating change  »

Salvatore Ferragamo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:35
01/21/19
01/21
08:35
01/21/19
08:35
General news
FX Action: USD-CAD has nudged back above 1.3300 »

FX Action: USD-CAD has…

PRDSY

Prada

$0.00

(0.00%)

08:34
01/21/19
01/21
08:34
01/21/19
08:34
Upgrade
Prada rating change  »

Prada upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANDY

Pandora A/S

$0.00

(0.00%)

08:33
01/21/19
01/21
08:33
01/21/19
08:33
Downgrade
Pandora A/S rating change  »

Pandora A/S downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGGF

SolGold

$0.00

(0.00%)

08:32
01/21/19
01/21
08:32
01/21/19
08:32
Initiation
SolGold initiated  »

SolGold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCFBY

Pacific Basin Shipping

$0.00

(0.00%)

08:30
01/21/19
01/21
08:30
01/21/19
08:30
Upgrade
Pacific Basin Shipping rating change  »

Pacific Basin Shipping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
01/21/19
01/21
08:30
01/21/19
08:30
General news
Oil Action: Front-month WTI futures are near flat »

Oil Action: Front-month…

WFAFY

Wesfarmers

$0.00

(0.00%)

08:27
01/21/19
01/21
08:27
01/21/19
08:27
Downgrade
Wesfarmers rating change  »

Wesfarmers downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTOKY

Rentokil

$0.00

(0.00%)

08:26
01/21/19
01/21
08:26
01/21/19
08:26
Downgrade
Rentokil rating change  »

Rentokil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNTGY

Brenntag

$0.00

(0.00%)

08:25
01/21/19
01/21
08:25
01/21/19
08:25
Upgrade
Brenntag rating change  »

Brenntag upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:25
01/21/19
01/21
08:25
01/21/19
08:25
General news
Oil Action: Front-month WTI futures are near flat »

Oil Action: Front-month…

LOIMF

Loomis AB

$0.00

(0.00%)

08:24
01/21/19
01/21
08:24
01/21/19
08:24
Downgrade
Loomis AB rating change  »

Loomis AB downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank; also use SFTBF

$0.00

(0.00%)

08:21
01/21/19
01/21
08:21
01/21/19
08:21
Initiation
SoftBank; also use SFTBF initiated  »

SoftBank initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:00
01/21/19
01/21
07:00
01/21/19
07:00
General news
FX Update: There hasn't been a strong theme »

FX Update: There…

CYDY

CytoDyn

$0.00

(0.00%)

04:55
01/21/19
01/21
04:55
01/21/19
04:55
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

03:45
01/21/19
01/21
03:45
01/21/19
03:45
General news
FX Action: USD-CAD has settled back in the upper 1.3200s »

FX Action: USD-CAD has…

03:05
01/21/19
01/21
03:05
01/21/19
03:05
General news
FX Update: The Dollar majors have been trading with little directional bias »

FX Update: The Dollar…

MET

MetLife

$45.32

0.28 (0.62%)

19:55
01/20/19
01/20
19:55
01/20/19
19:55
Hot Stocks
MetLife announces Richard Nunn as new CEO for Australia »

MetLife announced Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 18

    Jun

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

, TSLA

Tesla

$302.26

-45.18 (-13.00%)

19:27
01/20/19
01/20
19:27
01/20/19
19:27
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

TSLA

Tesla

$302.26

-45.18 (-13.00%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

EA

Electronic Arts

$92.50

3.19 (3.57%)

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

CMCSA

Comcast

$36.21

0.32 (0.89%)

CMCSK

Comcast

$0.00

(0.00%)

COST

Costco

$213.59

2.15 (1.02%)

ILMN

Illumina

$312.66

2.53 (0.82%)

TMO

Thermo Fisher

$240.72

2.55 (1.07%)

DHR

Danaher

$107.43

1.88 (1.78%)

A

Agilent

$71.93

1.16 (1.64%)

TECH

Bio-Techne

$163.24

1.16 (0.72%)

NEM

Newmont Mining

$31.77

0.15 (0.47%)

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

KRC

Kilroy Realty

$68.23

0.21 (0.31%)

VNO

Vornado

$66.40

1.04 (1.59%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 05

    Feb

  • 05

    Feb

  • 05

    Feb

  • 12

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

NTDOY

Nintendo

$0.00

(0.00%)

17:55
01/20/19
01/20
17:55
01/20/19
17:55
Periodicals
Nintendo investors starting to feel optimistic again, Bloomberg says »

Nintendo investors,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.